RT Journal Article
SR Electronic
T1 Estimating the infection fatality risk of COVID-19 in New York City during the spring 2020 pandemic wave
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.27.20141689
DO 10.1101/2020.06.27.20141689
A1 Wan Yang
A1 Sasikiran Kandula
A1 Mary Huynh
A1 Sharon K. Greene
A1 Gretchen Van Wye
A1 Wenhui Li
A1 Hiu Tai Chan
A1 Emily McGibbon
A1 Alice Yeung
A1 Don Olson
A1 Anne Fine
A1 Jeffrey Shaman
YR 2020
UL http://medrxiv.org/content/early/2020/09/14/2020.06.27.20141689.abstract
AB Background As the COVID-19 pandemic continues to unfold, the infection fatality risk (IFR, i.e. risk of death among all infections including asymptomatic and mild infections) is crucial for gauging the burden of death due to COVID-19 in the coming months or years. Here we estimate the IFR of COVID-19 in New York City (NYC), the first epidemic center in the United States where the IFR remains unclear.Methods We developed a meta-population network model-inference system to estimate underlying SARS-CoV-2 infection rates in NYC during the 2020 spring pandemic wave using case, mortality, and mobility data. Based on these estimates, we further estimated the IFR for all ages overall and for 5 age groups (i.e. <25, 25-44, 45-64, 65-74, and 75+ years) separately, during March 1 – June 6, 2020 (i.e., before NYC began its phased reopening).Findings During March 1 – June 6, 2020, 205,639 laboratory-confirmed COVID-19 cases were diagnosed and 21,447 confirmed and probable COVID-19 deaths occurred among NYC residents. We estimated an overall IFR of 1.39% (95% Credible Interval: 1.04-1.77%) in NYC. Estimated IFR for the two oldest age groups (65-74 and 75+ years) was much higher than the younger age groups and about double estimates reported for elsewhere. In particular, weekly IFR was estimated as high as 6.7% for 65-74 year-olds and 19.1% for 75+ year-olds.Interpretation These results are based on more complete ascertainment of COVID-19-associated deaths in NYC and thus likely more accurately reflect the true, higher burden of death due to COVID-19 than previously reported elsewhere.Competing Interest StatementJS and Columbia University disclose partial ownership of SK Analytics. JS discloses consulting for BNI and Merck. Other authors declare no conflict of interest.Funding StatementThis study was supported by the National Institute of Allergy and Infectious Diseases (AI145883), the National Science Foundation Rapid Response Research Program (RAPID; 2027369), and the NYC DOHMH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was classified as public health surveillance and exempt from ethical review and informed consent by the Institutional Review Boards of both Columbia University and New York City Department of Health and Mental Hygiene. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCOVID-19 case and mortality data for New York City publicly available from https://github.com/nychealth/coronavirus-data